U.S. pharma large copyright scrapped two experimental weight loss products last year—a once-every day capsule, lotiglipron, as a consequence of elevated liver enzymes along with a two times-each day tablet, danuglipron, as a consequence of solid side effects—but CEO Albert Bourla has said the company is determined to “play and earn” while i